PlanetMed Sp. z o.o.

The trials here

What the 32 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis18 trials
• Crohn's disease11 trials
• Primary biliary cholangitis2 trials
• Coeliac disease1 trial
• Liver cirrhosis1 trial

Phase

• Phase 214 trials
• Phase 314 trials
• Phase 13 trials
• Phase 1/21 trial

Status

• Completed13 trials
• Recruiting11 trials
• Active, not recruiting7 trials
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• Hoffmann-La Roche3 trials
• Takeda3 trials
• Abivax S.A.2 trials
• AstraZeneca2 trials
• and 17 more

Running trials

• Recruiting

  An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

  NCT07665723· Phase 1· Hoffmann-La Roche· Source

• Recruiting

  Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

  NCT07513181· Phase 2· Athos Therapeutics Inc· Source

• Recruiting

  A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

  NCT07374471· Phase 1/2· Mage Biologics· Source

• Recruiting

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

  NCT06975722· Phase 2· Sanofi· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

  NCT06958536· Phase 2· Sanofi· Source

• Recruiting

  A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  NCT06764615· Phase 2· Takeda· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

  NCT06636656· Phase 2· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet

  2023-506150-21-00· Phase 2· Dr. Falk Pharma GmbH· Source

• Active, not recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06254950· Phase 2· Takeda· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Takeda· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease5 recruiting
• Ulcerative colitis5 recruiting
• Primary biliary cholangitis2 recruiting
• Coeliac disease1 recruiting

Closed trials

• Active, not recruiting

  A trial to learn how safe AZD7798 is and how well it works in adults with ileal Crohn’s disease who have an ileostomy

  2024-514407-33-00· Phase 2· AstraZeneca AB· Source

• Completed

  A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.

  NCT06176560· Phase 3· Faes Farma S.A.· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Genentech Inc.· Source

• Completed

  A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

  NCT06269484· Phase 2· AstraZeneca· Source

• Completed

  Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis

  2022-503005-38-00· Phase 2· Landos Biopharma Inc.· Source

• Completed

  A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.

  2022-502778-18-00· Phase 3· Polpharma Biologics S.A.· Source

• Completed

  A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis

  NCT06080048· Phase 1· Sorriso Pharmaceuticals, Inc.· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  A Phase 1 Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Mild to Moderate Crohn's Disease

  NCT05542355· Phase 1· Exeliom Biosciences· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source